{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T03:24:01Z","timestamp":1762917841601},"reference-count":29,"publisher":"Scientific Scholar","issue":"01","license":[{"start":{"date-parts":[[2019,9,2]],"date-time":"2019-09-02T00:00:00Z","timestamp":1567382400000},"content-version":"vor","delay-in-days":609,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Neurosciences in Rural Practice"],"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>\n          Introduction: The antinociceptive effect of botulinum toxin-A (BTX-A) in trigeminal neuralgia (TN) has been described. We evaluated effects of BTX-A in relieving pain in patients with refractory TN at National Hospital of Sri Lanka. Materials and Methods: Pain in patients with TN was assessed using a visual analog from 0 to 10. Three months after commencement of drug therapy with \u22652 drugs including one first-line drug (carbamazepine\/oxcarbazepine), pain scores were re-assessed. Twenty-two patients who did not report improvement of \u226550% at 90 days\u2019 posttreatment were recruited. They were given adjunct BTX-A directly to the trigger point (if identified) or intradermal. Pain scores were assessed at 10, 20, 30, 60, and 90 days\u2019 posttreatment. Results: There was a statistically significant improvement in mean pain scores at 10, 20, 30, 60, and 90 days\u2019 posttreatment (5.59 [standard deviation (SD) = 2.7], 5.68 [SD = 2.6], 5.27 [SD = 3.2], 4.77 [SD = 3.7], and 5.32 [SD = 4.0]) compared to pre-BTX-A treatment (7.14, SD = 2.2). Percentage reduction in mean pain score ranged from 20.4% to 33.1%. Maximum response was at day 60 post-BTX-A (50% had \u226550% reduction in pain). No significant difference was found in response with higher doses and injection strategy. Conclusion: Consistent statistically significant reductions in pain scores at the aforesaid intervals compared to pretreatment means that there is a place for BTX in refractory TN.<\/jats:p>","DOI":"10.4103\/jnrp.jnrp_346_17","type":"journal-article","created":{"date-parts":[[2018,1,19]],"date-time":"2018-01-19T09:40:49Z","timestamp":1516354849000},"page":"100-105","source":"Crossref","is-referenced-by-count":13,"title":["Efficacy of Botulinum Toxin Type A in Trigeminal Neuralgia in a South Asian Cohort"],"prefix":"10.25259","volume":"09","author":[{"given":"Manjula Chandragomi","family":"Caldera","sequence":"additional","affiliation":[{"name":"Teaching Hospital Anuradhapura, Sri Lanka"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sameera Jayan","family":"Senanayake","sequence":"additional","affiliation":[{"name":"Family Health Bureau, Sri Lanka"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sujith Priyankara","family":"Perera","sequence":"additional","affiliation":[{"name":"Teaching Hospital Anuradhapura, Sri Lanka"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadeeke Nidhan","family":"Perera","sequence":"additional","affiliation":[{"name":"Peripheral Hospital Pamunugama, Sri Lanka"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ranjanie","family":"Gamage","sequence":"additional","affiliation":[{"name":"National Hospital of Sri Lanka, Sri Lanka"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inuka Kishara","family":"Gooneratne","sequence":"additional","affiliation":[{"name":"National Hospital of Sri Lanka, Sri Lanka"},{"name":"Kegalle District General Hospital, Sri Lanka"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10894","published-online":{"date-parts":[[2019,9,2]]},"reference":[{"key":"key-10.4103\/0976-3147.223507-1","first-page":"1239","volume-title":"Medical management of trigeminal neuropathic pains","author":"Zakrzewska","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"key-10.4103\/0976-3147.223507-2","first-page":"107","volume-title":"Treatment options in trigeminal neuralgia","author":"Obermann","year":"2010","journal-title":"Ther Adv Neurol Disord"},{"key":"key-10.4103\/0976-3147.223507-3","first-page":"1467","volume-title":"Gabapentin for idiopathic trigeminal neuralgia: Report of two cases","author":"Sist","year":"1997","journal-title":"Neurology"},{"key":"key-10.4103\/0976-3147.223507-4","first-page":"1714","volume-title":"Clinical effectiveness of lamotrigine and plasma levels in essential and symptomatic trigeminal neuralgia","author":"Lunardi","year":"1997","journal-title":"Neurology"},{"key":"key-10.4103\/0976-3147.223507-5","first-page":"155","volume-title":"The management of tic douloureux","author":"Loeser","year":"1977","journal-title":"Pain"},{"key":"key-10.4103\/0976-3147.223507-6","first-page":"CD004029","volume-title":"Non-antiepileptic drugs for trigeminal neuralgia","author":"He","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"key-10.4103\/0976-3147.223507-7","first-page":"243","volume-title":"Various surgical modalities for trigeminal neuralgia: Literature study of respective long-term outcomes","author":"Tatli","year":"2008","journal-title":"Acta Neurochir (Wien)"},{"key":"key-10.4103\/0976-3147.223507-8","first-page":"79","volume-title":"Linac radiosurgery as a tool in neurosurgery","author":"Deinsberger","year":"2005","journal-title":"Neurosurg Rev"},{"key":"key-10.4103\/0976-3147.223507-9","first-page":"37","volume-title":"Percutaneous retrogasserian glycerol rhizolysis for treatment of trigeminal neuralgia.Technique and results in 191 patients","author":"Cappabianca","year":"1995","journal-title":"J Neurosurg Sci"},{"key":"key-10.4103\/0976-3147.223507-10","first-page":"248","volume-title":"Trigeminal neuralgia.A practical approach to treatment","author":"Dalessio","year":"1982","journal-title":"Drugs"},{"key":"key-10.4103\/0976-3147.223507-11","first-page":"21","volume-title":"The use of botulinum toxin for the treatment of chronic facial pain","author":"Borodic","year":"2002","journal-title":"J Pain"},{"key":"key-10.4103\/0976-3147.223507-12","first-page":"106","volume-title":"Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles","author":"Ishikawa","year":"2000","journal-title":"Jpn J Ophthalmol"},{"key":"key-10.4103\/0976-3147.223507-13","first-page":"4981","volume-title":"Activation of TRPV1 mediates calcitonin gene-related peptide release, which excites trigeminal sensory neurons and is attenuated by a retargeted botulinum toxin with anti-nociceptive potential","author":"Meng","year":"2009","journal-title":"J Neurosci"},{"key":"key-10.4103\/0976-3147.223507-14","first-page":"9","volume-title":"The international classification of headache disorders: 2nd edition","author":"Headache","year":"2004","journal-title":"Cephalalgia"},{"key":"key-10.4103\/0976-3147.223507-15","first-page":"831094","volume-title":"Role of botulinum toxin type-A (BTX-A) in the management of trigeminal neuralgia","author":"Verma","year":"2013","journal-title":"Pain Res Treat"},{"key":"key-10.4103\/0976-3147.223507-16","first-page":"785","volume-title":"Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A","author":"Aoki","year":"2005","journal-title":"Neurotoxicology"},{"key":"key-10.4103\/0976-3147.223507-17","first-page":"1740","volume-title":"Hemifacial spasm: Clinical findings and treatment","author":"Wang","year":"1998","journal-title":"Muscle Nerve"},{"key":"key-10.4103\/0976-3147.223507-18","first-page":"443","volume-title":"Botulinum toxin type A for the treatment of trigeminal neuralgia: Results from a randomized, double-blind, placebo-controlled trial","author":"Wu","year":"2012","journal-title":"Cephalalgia"},{"key":"key-10.4103\/0976-3147.223507-19","first-page":"1306","volume-title":"An open study of botulinum-A toxin treatment of trigeminal neuralgia","author":"Piovesan","year":"2005","journal-title":"Neurology"},{"key":"key-10.4103\/0976-3147.223507-20","first-page":"43","volume-title":"Therapeutic effect of botulinum toxin-A in 88 patients with trigeminal neuralgia with 14-month follow-up","author":"Li","year":"2014","journal-title":"J Headache Pain"},{"key":"key-10.4103\/0976-3147.223507-21","first-page":"72","volume-title":"Therapeutic efficacy and safety of botulinum toxin type A in trigeminal neuralgia: A systematic review","author":"Hu","year":"2013","journal-title":"J Headache Pain"},{"key":"key-10.4103\/0976-3147.223507-22","doi-asserted-by":"crossref","unstructured":"Sridharan K, Sivaramakrishnan G. Interventions for refractory trigeminal neuralgia: A Bayesian mixed treatment comparison network meta-analysis of randomized controlled clinical trials. Clin Drug Investig 2017. doi: 10.1007\/s40261-017-0553-9.","DOI":"10.1007\/s40261-017-0553-9"},{"key":"key-10.4103\/0976-3147.223507-23","first-page":"92","volume-title":"Botulinum toxin-type A: Could it be an effective treatment option in intractable trigeminal neuralgia?","author":"Shehata","year":"2013","journal-title":"J Headache Pain"},{"key":"key-10.4103\/0976-3147.223507-24","first-page":"65","volume-title":"Two doses of botulinum toxin type A for the treatment of trigeminal neuralgia: Observation of therapeutic effect from a randomized, double-blind, placebo-controlled trial","author":"Zhang","year":"2014","journal-title":"J Headache Pain"},{"key":"key-10.4103\/0976-3147.223507-25","first-page":"161","volume-title":"Botulinum toxin and intractable trigeminal neuralgia","author":"T\u00fcrk","year":"2005","journal-title":"Clin Neuropharmacol"},{"key":"key-10.4103\/0976-3147.223507-26","first-page":"492","volume-title":"A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches","author":"Relja","year":"2007","journal-title":"Cephalalgia"},{"key":"key-10.4103\/0976-3147.223507-27","first-page":"293","volume-title":"Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: A randomized, double-blind, placebo-controlled trial","author":"Mathew","year":"2005","journal-title":"Headache"},{"key":"key-10.4103\/0976-3147.223507-28","first-page":"1126","volume-title":"Botulinum toxin type A for the prophylactic treatment of chronic daily headache: A randomized, double-blind, placebo-controlled trial","author":"Silberstein","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"key-10.4103\/0976-3147.223507-29","first-page":"877","volume-title":"OnabotulinumtoxinA for trigeminal neuralgia: A review of the available data","author":"Kowacs","year":"2015","journal-title":"Arq Neuropsiquiatr"}],"container-title":["Journal of Neurosciences in Rural Practice"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.4103\/jnrp.jnrp_346_17.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,5]],"date-time":"2023-08-05T04:17:43Z","timestamp":1691209063000},"score":1,"resource":{"primary":{"URL":"https:\/\/ruralneuropractice.com\/efficacy-of-botulinum-toxin-type-a-in-trigeminal-neuralgia-in-a-south-asian-cohort\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":29,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2019,9,2]]},"published-print":{"date-parts":[[2018,1]]}},"URL":"https:\/\/doi.org\/10.4103\/jnrp.jnrp_346_17","relation":{},"ISSN":["0976-3147","0976-3155"],"issn-type":[{"value":"0976-3147","type":"print"},{"value":"0976-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1]]}}}